Gemcitabine plus sirolimus for relapsed and progressing osteosarcoma patients after standard chemotherapy: a multicenter, single-arm phase II trial of Spanish Group for Research on Sarcoma (GEIS)
暂无分享,去创建一个
J. Mora | J. Martín-Broto | A. Carnero | C. Valverde | M. Tarón | A. Redondo | D. Moura | N. Hindi | A. López-pousa | R. Diaz-Beveridge | A. Gutiérrez | C. Tous | A. Carranza | X. García del Muro | J. Cruz | J. Martínez-Trufero | D. Marcilla | P. Sancho | X. D. Muro | M. Vaz | P. Luna | Pablo Luna | A. Carnero | V. Encinas | A. Gutiérrez
[1] S. Ferrari,et al. Gemcitabine and docetaxel in relapsed and unresectable high-grade osteosarcoma and spindle cell sarcoma of bone , 2016, BMC Cancer.
[2] L. Spector,et al. Prevalence of Metastasis at Diagnosis of Osteosarcoma: An International Comparison , 2016, Pediatric blood & cancer.
[3] Bob van de Water,et al. MEK inhibition induces apoptosis in osteosarcoma cells with constitutive ERK1/2 phosphorylation , 2015, Genes & cancer.
[4] S. Millis,et al. Multi-platform profiling of over 2000 sarcomas: Identification of biomarkers and novel therapeutic targets , 2015, Oncotarget.
[5] Xin Xiao,et al. The Role of Chemotherapy for Metastatic, Relapsed and Refractory Osteosarcoma , 2014, Pediatric Drugs.
[6] Sheng-Xi Wu,et al. Prognostic value of p53 alterations in human osteosarcoma: a meta analysis. , 2014, International journal of clinical and experimental pathology.
[7] H. Colom,et al. Phase I study and preclinical efficacy evaluation of the mTOR inhibitor sirolimus plus gemcitabine in patients with advanced solid tumours , 2014, British Journal of Cancer.
[8] K. S. Hall,et al. High‐dose chemotherapy with stem cell rescue in the primary treatment of metastatic and pelvic osteosarcoma: Final results of the ISG/SSG II study , 2014, Pediatric blood & cancer.
[9] T. He,et al. The Current and Future Therapies for Human Osteosarcoma. , 2013, Current cancer therapy reviews.
[10] Dafydd G. Thomas,et al. Results of a phase II study of sirolimus and cyclophosphamide in patients with advanced sarcoma. , 2012, European journal of cancer.
[11] Yang Yao,et al. Efficacy and safety of gemcitabine-docetaxel combination therapy for recurrent or refractory high-grade osteosarcoma in China: a retrospective study of 18 patients. , 2012, Japanese journal of clinical oncology.
[12] S. Ferrari,et al. A phase II trial of second-line pemetrexed in adults with advanced/metastatic osteosarcoma. , 2012, European journal of cancer.
[13] J. Wathen,et al. Phase II study of sequential gemcitabine followed by docetaxel for recurrent Ewing sarcoma, osteosarcoma, or unresectable or locally recurrent chondrosarcoma: results of Sarcoma Alliance for Research Through Collaboration Study 003. , 2012, The oncologist.
[14] P. Casali,et al. A phase II trial of sorafenib in relapsed and unresectable high-grade osteosarcoma after failure of standard multimodal therapy: an Italian Sarcoma Group study. , 2012, Annals of oncology : official journal of the European Society for Medical Oncology.
[15] C. Dumontet,et al. The ribonucleotide reductase large subunit (RRM1) as a predictive factor in patients with cancer. , 2011, The Lancet. Oncology.
[16] Yong Zhu,et al. mTOR/p70S6K Signal transduction pathway contributes to osteosarcoma progression and patients’ prognosis , 2010, Medical oncology.
[17] B. Massimo,et al. Phase 2 trial of two courses of cyclophosphamide and etoposide for relapsed high‐risk osteosarcoma patients , 2009 .
[18] L. Mirabello,et al. Osteosarcoma incidence and survival rates from 1973 to 2004 , 2009, Cancer.
[19] M Beth McCarville,et al. Combination of gemcitabine and docetaxel in the treatment of children and young adults with refractory bone sarcoma , 2008, Cancer.
[20] L. Helman,et al. Rapamycin inhibits ezrin-mediated metastatic behavior in a murine model of osteosarcoma. , 2005, Cancer research.
[21] G. Bepler,et al. Ribonucleotide Reductase Messenger RNA Expression and Survival in Gemcitabine/Cisplatin-Treated Advanced Non-Small Cell Lung Cancer Patients , 2004, Clinical Cancer Research.
[22] G. Demetri,et al. Phase II study of ecteinascidin 743 in heavily pretreated patients with recurrent osteosarcoma , 2003, Cancer.
[23] S. Ferrari,et al. Postrelapse survival in osteosarcoma of the extremities: prognostic factors for long-term survival. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[24] R. Benjamin,et al. High-dose ifosfamide in bone and soft tissue sarcomas: results of phase II and pilot studies--dose-response and schedule dependence. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[25] P. Casali,et al. Sorafenib and everolimus for patients with unresectable high-grade osteosarcoma progressing after standard treatment: a non-randomised phase 2 clinical trial. , 2015, The Lancet. Oncology.
[26] E. Kleinerman,et al. Participation of the Fas/FasL signaling pathway and the lung microenvironment in the development of osteosarcoma lung metastases. , 2014, Advances in experimental medicine and biology.
[27] P. Rose. Survival after recurrent osteosarcoma: Data from 3 European Osteosarcoma Intergroup (EOI) randomized controlled trials , 2012 .
[28] J. Blay,et al. Phase II study of the mammalian target of rapamycin inhibitor ridaforolimus in patients with advanced bone and soft tissue sarcomas. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[29] S. Ferrari,et al. Phase 2 trial of two courses of cyclophosphamide and etoposide for relapsed high‐risk osteosarcoma patients , 2009, Cancer.